Related references
Note: Only part of the references are listed.TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Connor S. Clairmont et al.
NATURE CELL BIOLOGY (2020)
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
Andrew D. Simmons et al.
BMC CANCER (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
Yihan Peng et al.
NATURE COMMUNICATIONS (2019)
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Elizabeth L. Christie et al.
NATURE COMMUNICATIONS (2019)
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
Rachel M. Hurley et al.
GYNECOLOGIC ONCOLOGY (2019)
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
Aubrey L. Miller et al.
EBIOMEDICINE (2019)
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Defining and Modulating 'BRCAness'
Andrea K. Byrum et al.
TRENDS IN CELL BIOLOGY (2019)
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
Jian-Fang Ning et al.
NATURE COMMUNICATIONS (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review
Anna Maria Militello et al.
FRONTIERS IN ONCOLOGY (2019)
Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51
Lin Zhao et al.
CANCER SCIENCE (2019)
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation
Rachel Abbotts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
Kamila Burdova et al.
CELLS (2019)
Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
Bhanvi Mishra et al.
CANCER BIOLOGY & THERAPY (2019)
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Marco Barazas et al.
CANCER RESEARCH (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
Antonio Marzio et al.
MOLECULAR CELL (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Yifan Wang et al.
NATURE COMMUNICATIONS (2019)
Acetylation of 53BP1 dictates the DNA double strand break repair pathway
Xiang Guo et al.
NUCLEIC ACIDS RESEARCH (2018)
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
X. Bian et al.
ONCOGENE (2018)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola et al.
CANCER CELL (2018)
Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression
Yu-Ting Wang et al.
CANCER SCIENCE (2018)
DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
Rajat Gupta et al.
CELL (2018)
DNA repair and cell cycle checkpoint defects in a mouse model of BRCAness' are partially rescued by 53BP1 deletion
Sarah M. Misenko et al.
CELL CYCLE (2018)
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Erica L. Gornstein et al.
CLINICAL BREAST CANCER (2018)
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Nicholas Pulliam et al.
CLINICAL CANCER RESEARCH (2018)
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2018)
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander et al.
LANCET ONCOLOGY (2018)
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
Steven T. Sizemore et al.
MOLECULAR CANCER RESEARCH (2018)
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Harveer Dev et al.
NATURE CELL BIOLOGY (2018)
Acetylation blocks DNA damage-induced chromatin ADP-ribosylation
Glen Liszczak et al.
NATURE CHEMICAL BIOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
Khyati Meghani et al.
CELL REPORTS (2018)
HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress
Brandt A. Nichols et al.
CANCER RESEARCH (2018)
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
Hongwei Liao et al.
EMBO REPORTS (2018)
The shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer et al.
NATURE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
Yizhou Joseph He et al.
NATURE (2018)
BET Inhibition Induces HEXIM1-and RAD51-Dependent Conflicts between Transcription and Replication
Akhil Bowry et al.
CELL REPORTS (2018)
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations
Benedito A. Carneiro et al.
JCO PRECISION ONCOLOGY (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Yajing Liu et al.
CLINICAL CANCER RESEARCH (2017)
Mechanisms of DNA Damage, Repair, and Mutagenesis
Nimrat Chatterjee et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2017)
Reverse the Resistance to PARP Inhibitors
Yevgeniy Kim et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma
Jianfang Ning et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang et al.
LANCET ONCOLOGY (2017)
Restoration of Replication Fork Stability in BRCA1-and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
Angelo Taglialatela et al.
MOLECULAR CELL (2017)
RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks
Huzefa Dungrawala et al.
MOLECULAR CELL (2017)
PARPi focus the spotlight on replication fork protection in cancer
Katharina Schlacher
NATURE CELL BIOLOGY (2017)
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli et al.
NATURE CELL BIOLOGY (2017)
The control of DNA repair by the cell cycle
Nicole Hustedt et al.
NATURE CELL BIOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation
Mayu Isono et al.
CELL REPORTS (2017)
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma
Jianfang Ning et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
Paul Mayor et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response
Zhiguo Li et al.
CANCER RESEARCH (2017)
ATM Deficiency Is Associated with Sensitivity to PARP1-and ATR Inhibitors in Lung Adenocarcinoma
Anna Schmitt et al.
CANCER RESEARCH (2017)
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Brian G. Czito et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Michael J. Pishvaian et al.
BRITISH JOURNAL OF CANCER (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication
Stephen K. Godin et al.
BIOCHEMISTRY AND CELL BIOLOGY (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity
Pavel Moudry et al.
JOURNAL OF CELL BIOLOGY (2016)
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance
Yifan Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
Carine Robert et al.
LEUKEMIA RESEARCH (2016)
HELB Is a Feedback Inhibitor of DNA End Resection
Jan Tkac et al.
MOLECULAR CELL (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du et al.
NATURE MEDICINE (2016)
FANCD2 limits replication stress and genome instability in cells lacking BRCA2
Johanna Michl et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction
Anthony M. Couturier et al.
NUCLEIC ACIDS RESEARCH (2016)
Histone Modifications and Cancer
James E. Audia et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
FANCD2 limits replication stress and genome instability in cells lacking BRCA2
Johanna Michl et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
Young Eun Choi et al.
CELL REPORTS (2016)
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Shawn F. Johnson et al.
CELL REPORTS (2016)
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair
Zeina Kais et al.
CELL REPORTS (2016)
A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy
Wenpeng Liu et al.
EBIOMEDICINE (2016)
DNA repair, genome stability and cancer: a historical perspective
Penny A. Jeggo et al.
NATURE REVIEWS CANCER (2016)
Hereditary breast and ovarian cancer: new genes in confined pathways
Finn Cilius Nielsen et al.
NATURE REVIEWS CANCER (2016)
PTEN regulates RPA1 and protects DNA replication forks
Guangxi Wang et al.
CELL RESEARCH (2015)
DNA End Resection: Nucleases Team Up with the Right Partners to Initiate Homologous Recombination
Petr Cejka
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
Minesh P. Mehta et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Sebastian Eustermann et al.
MOLECULAR CELL (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line
Federica Baldan et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Kim A. Reiss et al.
CLINICAL CANCER RESEARCH (2015)
RECQL5 and BLM exhibit divergent functions in cells defective for the Fanconi anemia pathway
Tae Moon Kim et al.
NUCLEIC ACIDS RESEARCH (2015)
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min et al.
BREAST CANCER RESEARCH (2015)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Peter Bouwman et al.
CLINICAL CANCER RESEARCH (2014)
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Poorval M. Joshi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
Marie-France aEuro Langelier et al.
NUCLEIC ACIDS RESEARCH (2014)
Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice
Nozomi Tomimatsu et al.
NATURE COMMUNICATIONS (2014)
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
Young Eun Choi et al.
ONCOTARGET (2014)
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Kyungsoo Ha et al.
ONCOTARGET (2014)
Is Non-Homologous End-Joining Really an Inherently Error-Prone Process?
Mireille Betermier et al.
PLOS GENETICS (2014)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
J. Ross Chapman et al.
MOLECULAR CELL (2013)
A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
Cristina Escribano-Diaz et al.
MOLECULAR CELL (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark
Amelie Fradet-Turcotte et al.
NATURE (2013)
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Stephen J. Pettitt et al.
PLOS ONE (2013)
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Neil Johnson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Michal Zimmermann et al.
SCIENCE (2013)
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Michela Di Virgilio et al.
SCIENCE (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Substrate-Selective Repair and Restart of Replication Forks by DNA Translocases
Remy Betous et al.
CELL REPORTS (2013)
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
Katharina Schlacher et al.
CANCER CELL (2012)
Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Eddy S. Yang et al.
CANCER RESEARCH (2012)
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Lenka Oplustilova et al.
CELL CYCLE (2012)
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Michael Fraser et al.
CLINICAL CANCER RESEARCH (2012)
Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
Ketki Karanam et al.
MOLECULAR CELL (2012)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Double-Strand Break End Resection and Repair Pathway Choice
Lorraine S. Symington et al.
ANNUAL REVIEW OF GENETICS, VOL 45 (2011)
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage
Juhong Jiang et al.
CANCER RESEARCH (2011)
MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
Eduardo Vilar et al.
CANCER RESEARCH (2011)
Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
Katharina Schlacher et al.
CELL (2011)
Genetic Interactions in Cancer Progression and Treatment
Alan Ashworth et al.
CELL (2011)
Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
Sophie E. Polo et al.
GENES & DEVELOPMENT (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin D. Forster et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms
Aura Carreira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Regulation of Homologous Recombination in Eukaryotes
Wolf-Dietrich Heyer et al.
ANNUAL REVIEW OF GENETICS, VOL 44 (2010)
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria J. Weston et al.
BLOOD (2010)
DNA Damage-Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation
Hong Wang et al.
CANCER RESEARCH (2010)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Remi Buisson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor
Sushant K. Kachhap et al.
PLOS ONE (2010)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Xuesong Liu et al.
MOLECULAR CANCER RESEARCH (2009)
CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
Maximina H. Yun et al.
NATURE (2009)
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Shirley M. H. Sy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation
A Chalmers et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Share Paper
